AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tamoxifen substantially cuts the risk of invasive and noninvasive breast cancer, researchers confirmed in an extended follow-up of the National Surgical Adjuvant Breast and Bowel Project that was initially reported in 1998.
This update of the NSABP study involved 13,207 women at high risk of developing breast cancer who had participated in the initial study in 1992-1997 and were followed for an additional 7 years. A total of 6,597 subjects composed the tamoxifen group and 6,610 formed the placebo group.
All the benefits and risks of tamoxifen therapy that had been reported in the initial study were borne out in this extended study, according to Bernard Fisher, M.D., scientific director of the NSABP and distinguished surgical professor at the University of Pittsburgh.
Tamoxifen was linked to a 43% reduction in the cumulative rate of invasive breast cancer. The rate was 24.8 cancers/1,000 women taking tamoxifen, compared with 42.5/1,000 women taking placebo.
Similarly, tamoxifen reduced the cumulative rate of noninvasive breast cancer by 37%. The rate was 10.2 cancers/ 1,000 women taking tamoxifen, compared with 15.8/ 1,000 women taking placebo.
The drug cut the risk of breast cancer in all subgroups of subjects categorized by age, history of lobular carcinoma in situ (LCIS), history of atypical hyperplasia, and level of predicted risk of breast cancer.
Among those women who took tamoxifen, the incidence of breast cancer remained relatively constant throughout the 7 years of follow-up, remaining stable for at least 2 years after they had finished a 5-year course of the drug (J. Natl. Cancer Inst. 2005;97:1652-62).
Source: HighBeam Research, NSABP's tamoxifen results confirmed.(News)